Just to remind ourselves that Opthea is a anti VEGF drug and Fovista is a "platelet derived growth factor (PDGF)" drug so as not to confuse the Opthotech result and implications for OPT. More signs of efficacy from the phase 2A trial to be reported late 1st qtr 2017 for OPT302 will definitely put OPT centre stage.
http://www.ophthotech.com/product-candidates/fovista/
really really good, page-6
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.020(4.04%) |
Mkt cap ! $584.7M | |||
| Open | High | Low | Value | Volume |
| 49.5¢ | 50.8¢ | 47.5¢ | $4.304M | 9.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 29597 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 15044 | 2 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |